🔗 Share this article

Ministers and senior MPs have issued warnings that the United Kingdom's recent agreements with Donald Trump are "lacking a solid foundation." This follows revelations that a so-called "milestone" deal on drug pricing, which commits to zero tariffs in exchange for the NHS increasing its costs, lacks any detailed agreement beyond broad headline terms outlined by government press releases.

An Agreement in Principle Only

The US-UK pharmaceuticals agreement, hailed as a "generational" achievement, is still an "broad understanding" without detailed provisions. Observers point out that the official announcements from the UK and US governments present the deal in divergent terms. The British version emphasizes securing "duty-free access" as a singular success, while the American announcement concentrates on the expectation for the NHS to pay significantly more for new medications.

"The danger exists that the UK government has agreed to terms to increase medicine costs in return for nothing more than a assurance from President Trump," stated David Henig, a trade expert. "We know he has form for not keeping promises."

A Pattern of Unreliability

Worries have been intensified by Washington's recent decision to put on ice the high-value digital accord, which was previously heralded as "a transformative pact" in the bilateral relationship. The US pointed to a lack of progress from the UK on addressing wider trade issues as the reason for the pause.

Furthermore, concessions secured for British farmers as part of an initial accord have not been formally approved by the US, despite a fast-approaching January deadline. "It is our belief that the US has not finalized the reciprocal tariff rate quota," said Tom Bradshaw of the National Farmers' Union.

Anxiety Behind Closed Doors

In confidential discussions, ministers have voiced worries that the government's deals with Washington are unstable and unpredictable. One minister described the series of agreements as "built on sand," while another framed the situation as the "new normal" in the transatlantic relationship, marked by "increased uncertainty and instability."

Layla Moran, chair of the health select committee, remarked: "Perhaps most shocking than the US approach is the UK government's credulous faith that his administration is a good faith actor. The NHS is too precious to be gambled with."

Government Downplays Risks, Points to Gains

Government figures have attempted to minimize the chances of the US reneging on the pharmaceuticals deal. One source suggested the US pharmaceutical industry itself had been lobbying for the agreement, seeking certainty on imports and pricing, making it less abstract than the paused tech deal.

Officials concede that unpredictability is inherent in dealing with the current US leadership. However, they argue that the UK has achieved real benefits for businesses, such as preferential tariff rates compared to other nations. "The fact we have 25% steel tariffs, which is lower than the rate for the rest of the world, is a solid gain," one official said.

However, delays have emerged in implementing the initial US-UK accord. Promised reciprocal agricultural allowances have yet to be finalized, and the assurance to "eliminate duties on UK metals" has not been fulfilled, with tariffs remaining at 25%.

As negotiations continue, the two sides have agreed to resume talks on the paused tech prosperity deal in January, following what were described as "very positive" meetings between UK and US officials in Washington.